Headlands Technologies’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Headlands Technologies’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-2,602	Closed	-$265K	–	1273
2023 Q2	$265K	Buy	+2,602	New	+$246K	0.08%	243

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Headlands Technologies's RETA Position: Q3 2023 in Review

Headlands Technologies sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 2,602 shares — an estimated $265K sold.

Headlands Technologies first reported a position in RETA in Q2 2023 and held it in 1 quarter. The position peaked at $265K in Q2 2023. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

Headlands Technologies reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
Headlands Technologies sold 2,602 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $265K.
Headlands Technologies first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2023 and held it in 1 quarter.
Headlands Technologies's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $265K in Q2 2023.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on Headlands Technologies's 13F filing for Q3 2023, filed 9 Nov 2023.